Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr134.99M

Enterprise Valuekr107.45

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding126,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

Zero Debt / Conservatively Structured Balance SheetCarrying no financial debt materially lowers refinancing and interest-rate risk and preserves flexibility for clinical investment cycles. For a biotech with long R&D horizons, zero leverage reduces insolvency risk and gives management optionality for funding strategies, partnerships, or milestone financing.

Multi-year Revenue Growth TrendSustained top-line expansion across multiple years signals growing commercial traction for services or products, supporting scale economics over time. Persistent revenue growth, even amid losses, provides a foundation for improving margins as fixed-cost absorption improves and commercial programs mature.

Vertical Capabilities In Cell Therapies And ManufacturingOwning cell-banking and manufacturing capabilities is a structural advantage in cell therapy: it supports quality control, shortens development timelines, and enables capture of downstream manufacturing margins. This vertical stack strengthens partnership prospects and regulatory readiness.

Bears Say

Persistent Large Losses And Negative MarginsContinuous negative gross margins and large net losses indicate the core business has not yet reached sustainable profitability. Over the medium term this pressures capital needs, limits reinvestment capacity, and requires clear monetization of R&D to transition from burn to positive operating leverage.

High And Ongoing Cash BurnSevere negative operating and free cash flow implies continued reliance on equity or partner financing. Persistent cash burn constrains ability to fund trials or scale manufacturing without dilution or dilutive financing, raising execution risk and making long-term planning dependent on external capital access.

Declining Equity And Dilution RiskMaterial erosion of shareholder equity over time reflects cumulative losses and likely equity-funded operations, increasing dilution risk for existing holders. A shrinking equity base reduces financial buffers versus adverse outcomes and may limit strategic flexibility if further capital raises are needed.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr134.99M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 28 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.